Treatment Guidelines for Antiphospholipid Syndrome
Primary Prevention in Asymptomatic aPL-Positive Patients
Low-dose aspirin 75–100 mg daily is strongly recommended for all patients with high-risk antiphospholipid antibody profiles (triple-positive, double-positive, isolated lupus anticoagulant, or persistently high titers ≥40 Units) who have never had thrombosis. 1
- This recommendation applies equally to patients with systemic lupus erythematosus who carry high-risk aPL profiles 1
- For low-risk profiles (isolated anticardiolipin or anti-β2-glycoprotein I at low-to-medium titers), aspirin may be considered after shared decision-making 1
- All three aPL assays (lupus anticoagulant, anticardiolipin IgG/IgM, anti-β2-glycoprotein I IgG/IgM) must be positive on two separate occasions ≥12 weeks apart before initiating therapy 1, 2
- Aggressive cardiovascular risk-factor modification—smoking cessation, blood-pressure control, and lipid management—is essential in all asymptomatic carriers 1
Management of Thrombotic APS
Venous Thromboembolism
Lifelong warfarin targeting INR 2.0–3.0 is the standard of care for all patients with documented venous thrombosis (deep-vein thrombosis or pulmonary embolism) and persistent aPL positivity. 1, 2
- INR should be checked at least monthly, with more frequent testing if unstable 2
- Warfarin is strongly preferred over direct oral anticoagulants in all APS patients 1, 2
Arterial Thrombosis (Stroke, TIA, Myocardial Infarction)
Two evidence-based regimens are endorsed for arterial APS: 1, 2
- High-intensity warfarin targeting INR 3.0–4.0, or
- Moderate-intensity warfarin (INR 2.0–3.0) combined with low-dose aspirin 81 mg daily
- Arterial APS carries higher recurrence risk than venous APS and requires more aggressive anticoagulation 1, 2
- For recurrent thrombosis despite standard anticoagulation, escalate to high-intensity warfarin (INR 3.0–4.0) 2
Direct Oral Anticoagulants: Contraindicated
Rivaroxaban and all other DOACs are contraindicated in APS patients with prior thrombosis, especially those with triple-positive antibodies or arterial disease, due to excess recurrent thrombotic events compared with warfarin. 1, 2
- If a triple-positive APS patient is already on a DOAC, transition immediately to warfarin 1
- DOACs are associated with higher rates of arterial thrombosis, particularly stroke, in APS 1, 2
Management of Obstetric APS
Confirmed Obstetric APS (≥3 Early Losses or ≥1 Late Loss)
Combined low-dose aspirin (81–100 mg daily) plus prophylactic-dose low-molecular-weight heparin throughout pregnancy is strongly recommended, achieving approximately 70% live-birth rates. 1, 3
- Aspirin: Start before 16 weeks gestation and continue through delivery 1, 3
- Prophylactic LMWH dosing: Enoxaparin 40 mg SC once daily or dalteparin 5,000 U SC once daily 3
- Continue LMWH for 6–12 weeks postpartum to cover the heightened post-delivery thrombotic risk 1, 3
- This regimen carries Grade 1B evidence strength 3
Common pitfall: Despite treatment, preeclampsia occurs in ~34% and preterm delivery in ~43% of treated patients; close monitoring is essential 3
Thrombotic APS in Pregnancy (History of Thrombosis)
Therapeutic-dose LMWH plus low-dose aspirin throughout pregnancy and for a minimum of 6–12 weeks postpartum is required for all women with any prior thrombotic event. 1, 3
- Therapeutic LMWH dosing: Enoxaparin 1 mg/kg SC twice daily or dalteparin 100 U/kg SC twice daily 3
- Aspirin: 81–100 mg daily throughout pregnancy 3
- Full anticoagulation is essential because prior thrombosis adds substantial risk in the hypercoagulable pregnancy state 3
Asymptomatic aPL-Positive Pregnant Women (No Clinical APS)
Low-dose aspirin 81–100 mg daily alone is advised, started before 16 weeks and continued through delivery; routine prophylactic LMWH is conditionally recommended against. 1, 3
- LMWH may be considered only in very high-risk scenarios: triple-positive antibodies, strongly positive lupus anticoagulant, advanced maternal age, or IVF conception 1, 3
- The 2020 American College of Rheumatology guideline conditionally recommends against routine LMWH because evidence of benefit is insufficient and the drug carries known risks (bleeding, heparin-induced thrombocytopenia, osteoporosis) 3
Peripartum Anticoagulation Management
LMWH should be discontinued at least 24 hours before planned delivery or neuraxial anesthesia and resumed 6–12 hours after vaginal delivery or 12–24 hours after cesarean section once hemostasis is confirmed. 3
- Aspirin should be continued throughout labor and delivery because it does not interfere with neuraxial anesthesia 3
- Warfarin may be resumed after delivery for long-term anticoagulation, as it is compatible with breastfeeding 3
Critical contraindications: Vitamin K antagonists (warfarin) must be avoided in the first trimester (teratogenic) and after week 36 (risk of fetal intracranial hemorrhage) 3
Adjunctive Therapies
Hydroxychloroquine
Hydroxychloroquine 200–400 mg daily may be added to standard anticoagulation for patients with primary APS, particularly those with refractory manifestations, concurrent SLE, or obstetric APS with pregnancy loss despite aspirin plus heparin. 1, 2
- This is a conditional recommendation based on small emerging studies suggesting reduction in pregnancy complications 1, 3
- Hydroxychloroquine should be continued throughout pregnancy in patients with both APS and SLE 1
- Do not use hydroxychloroquine in asymptomatic aPL-positive women without another indication (e.g., SLE) 3
Statins
Statins may have a role in APS management due to their anti-inflammatory and immunomodulatory properties, particularly in high-risk patients. 1, 2
Management of Catastrophic APS
Aggressive treatment with a combination of immediate therapeutic anticoagulation (unfractionated heparin or LMWH), high-dose intravenous glucocorticoids (methylprednisolone 500–1,000 mg daily for 3–5 days, followed by oral prednisone 1 mg/kg/day), and plasma exchange is recommended. 1
- Plasma exchange is associated with improved patient survival in retrospective studies and should be initiated promptly 1
- Intravenous cyclophosphamide should be added if catastrophic APS occurs in the setting of SLE flare (typical dosing: 500–1,000 mg/m² monthly) 1
- Rituximab and eculizumab (complement C5 inhibitor) have emerging evidence of benefit in catastrophic APS 1
Monitoring and Follow-Up
Anticoagulation Monitoring
For venous APS, maintain INR 2.0–3.0; for arterial APS (high-intensity strategy), maintain INR 3.0–4.0. 1, 2
- INR should be checked at least monthly, with more frequent testing if unstable 2
- Critical caveat: In patients with lupus anticoagulant, the INR may not be representative of anticoagulation intensity due to interaction between lupus anticoagulant and the thromboplastin reagent 4
- Anti-Xa monitoring may be considered for therapeutic LMWH dosing or in patients with extreme body weight 3
Pregnancy Monitoring
Pregnant individuals with APS require monthly clinical assessments, serial fetal ultrasounds with Doppler starting at 16–20 weeks, blood-pressure checks at every visit, and laboratory monitoring of renal function and serological markers at least once per trimester. 1
- Rheumatology or high-risk obstetric visits at least once per trimester, with more frequent visits (every 2–4 weeks) for triple-positive, lupus-anticoagulant-positive, or concurrent SLE patients 1
- Monthly third-trimester Doppler assessments beginning at 28 weeks (umbilical artery, uterine arteries, ductus venosus, middle cerebral artery) 1
- Increase surveillance to every 1–2 weeks after 32 weeks or sooner if abnormalities are detected 1
- Monthly fetal biometry in the third trimester to detect intrauterine growth restriction, which occurs ~4.7-fold more frequently in high-risk APS 1
Therapies to Avoid
Prednisone should be strongly avoided as an adjunct to standard APS therapy; no controlled trials demonstrate benefit and the risk profile is unfavorable. 3